Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041396 | 0.92 | STAT3 (0.31) | STAT3 | |
| SCHEMBL4151482 | 0.87 | — | — | |
| SCHEMBL4151487 | 0.87 | — | — | |
| SCHEMBL9947088 | 0.86 | — | — | |
| SCHEMBL1604234 | 0.84 | STAT3 (0.35) | STAT3 | |
| SCHEMBL15457600 | 0.84 | STAT3 (0.35) | STAT3 | |
| SCHEMBL12749787 | 0.84 | — | — | |
| SCHEMBL14523029 | 0.81 | — | — | |
| SCHEMBL9010727 | 0.80 | — | — | |
| SCHEMBL13158123 | 0.80 | STAT3 (0.31) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8575136-B2 | 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| EP-1268415-B1 | 26,27-HOMOLOGATED-20-EPI-2-ALKYL-19-NOR-VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RES FOUND (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8404666-B2 | 2-substituted-1α,25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8222235-B2 | 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20030073857-A1 | 26,27-Homologated-20-epi-2-alkyl-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-04-17 | — | — | US | disclosed |
| US-6544969-B2 | Administering to a patient with metbolic bone disease an effective amount of a 26, 27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-04-08 | — | — | US | disclosed |
| EP-1268415-A1 | 26,27-HOMOLOGATED-20-EPI-2-ALKYL-19-NOR-VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0970047-B1 | 2-ALKYLIDENE-19-NOR-VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RES FOUND (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020123638-A1 | 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-09-05 | — | — | US | disclosed |
| US-6392071-B1 | ANTICANCER AGENTS | WISCONSIN ALUMNI: RESEARCH FOUNDATION | 2002-05-21 | — | — | US | disclosed |
| US-6316642-B1 | FOR THERAPY OF OSTEOPOROSIS AND PSORIASIS, AS ANTICANCER AGENT | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-11-13 | — | — | US | disclosed |
| WO-2001074765-A1 | 26,27-HOMOLOGATED-20-EPI-2-ALKYL-19-NOR-VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6277837-B1 | TREATMENT OF PSORIASIS, LEUKEMIA, CANCERS, OSTEOPOROSIS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-08-21 | — | — | US | disclosed |
| US-6127559-A | 2-alkyl-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | STAT3 415/4885 |
| US-20020123638-A1 | 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds | VDR, CYP24A1, CYP2R1 | STAT3 2974/4885 |
| US-20030073857-A1 | 26,27-Homologated-20-epi-2-alkyl-19-nor-vitamin D compounds | VDR, CYP24A1, CYP2R1 | STAT3 2974/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | STAT3 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.